JulieAnne G McGregor
Overview
Explore the profile of JulieAnne G McGregor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laurin L, Gasim A, Derebail V, McGregor J, Kidd J, Hogan S, et al.
Clin J Am Soc Nephrol
. 2016 Jul;
11(10):1752-1759.
PMID: 27445167
Background And Objectives: Idiopathic collapsing FSGS has historically been associated with poor renal outcomes. Minimal clinical data exist on the efficacy of immunosuppressive therapy. Our study sought to provide a...
2.
Bunch D, Mendoza C, Aybar L, Kotzen E, Colby K, Hu Y, et al.
Ann Rheum Dis
. 2015 May;
74(9):1784-6.
PMID: 25934841
No abstract available.
3.
McGregor J, Negrete-Lopez R, Poulton C, Kidd J, Katsanos S, Goetz L, et al.
Nephrol Dial Transplant
. 2015 Mar;
30 Suppl 1:i171-81.
PMID: 25805747
Background: Disease control in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with immunosuppression is effective but burdened by adverse events, especially infections. The study goal was to evaluate risks and...
4.
McGregor J, Hogan S, Kotzen E, Poulton C, Hu Y, Negrete-Lopez R, et al.
Nephrol Dial Transplant
. 2015 Mar;
30 Suppl 1:i123-31.
PMID: 25805743
Background: Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an...
5.
Berg E, McGregor J, Burkart M, Poulton C, Hu Y, Falk R, et al.
J Autoimmune Dis Rheumatol
. 2015 Jan;
2(3):74-91.
PMID: 25599078
Methods: AAV patients completed a CAM questionnaire between July 2011 and May 2012. Patients were 18 years or older and had biopsy proven and/or clinical evidence of AAV. Medical record...
6.
Lee T, Gasim A, Derebail V, Chung Y, McGregor J, Lionaki S, et al.
Clin J Am Soc Nephrol
. 2014 Mar;
9(5):905-13.
PMID: 24578329
Background And Objectives: In ANCA-associated GN, severe renal dysfunction portends a poor prognosis for renal recovery and patient survival. This study evaluated the prognostic factors affecting renal and patient outcomes...
7.
Bunch D, McGregor J, Khandoobhai N, Aybar L, Burkart M, Hu Y, et al.
Clin J Am Soc Nephrol
. 2013 Jan;
8(3):382-91.
PMID: 23293123
Background And Objectives: B cell significance in ANCA disease pathogenesis is underscored by the finding that ANCA alone can cause disease in mouse models and by the effectiveness of rituximab...
8.
9.
McGregor J, Hogan S, Hu Y, Jennette C, Falk R, Nachman P
Clin J Am Soc Nephrol
. 2011 Dec;
7(2):240-7.
PMID: 22134625
Background And Objectives: The optimal course of glucocorticoid therapy in anti-neutrophil cytoplasmic autoantibody (ANCA) disease is unknown. This cohort study evaluates effects of glucocorticoid therapy duration on patient outcomes and...
10.
Roth A, Brown M, Smith R, Badhwar A, Parente O, Chul Chung H, et al.
J Am Soc Nephrol
. 2011 Oct;
23(3):545-55.
PMID: 22021709
Lysosomal membrane protein 2 (LAMP-2) is a target of antineutrophil cytoplasmic autoantibodies (ANCA) in addition to the more commonly known targets proteinase 3 and myeloperoxidase. The prevalence of anti-LAMP-2 antibodies...